An expert consensus report on the clinical use of the Vycross^® hyaluronic acid VYC‐25 L filler

Abstract

Background:The portfolio of hyaluronic acid (HA) fillers and the techniques of administration have evolved in recent years. The latest innovation in the Vycross ® range was the introduction of VYC-25L (Juvéderm Volux ® ; Allergan plc), a first-in-class filler effective for chin and facial lower third remodeling. The aim here was to provide clinicians who are starting to use VYC-25L with key advice, and to standardize procedures so that optimal and predictable outcomes can be obtained. Methods: A multidisciplinary group of experts in esthetic medicine from Spain andPortugal reviewed the properties, treatment paradigms, administration techniques, and potential complications of VYC-25L, on the basis of which they drafted consensus recommendations for its clinical use. Results:The consensus panel provided specific recommendations focusing on the patient profile, dose, administration techniques, and the complications of VYC-25L and their management. The panel identified five different profiles of patients who may benefit from VYC-25L, and they drafted recommendations aimed to facilitate the treatment of these patients, namely, microgenia (women/men), masculinization (men), rejuvenation (women/men), facial laxity (women/men), and submental convexity (women/men). In terms of their safety, no specific recommendations were made beyond those established for other HA fillers. Conclusions:The evolution of esthetic medicine makes it necessary to update the clinical recommendations that guide patient assessment and treatment with the new HA fillers developed. The current consensus document addresses relevant issues related to the use of VYC-25L on different types of patient, in an attempt to standardize procedures and help specialists obtain predictable results.

Juvéderm: What we know now

“…Volux ® uses Vycross™ technology and has the highest concentration of HA of the Juvéderm product line (25 mg/mL), with results lasting about 18 months. 34 A phase 3, multisite, randomized, no-treatment controlled study was completed in the United States in July 2021, with the goal of FDA approval in the United States in the near future. 35 Juvéderm Volite ® XC is also seeking FDA approval in the US for improvement of overall skin topography on the head and neck.…”

“…Juvéderm Volux®, which was recently approved in the EU for chin and facial lower third remodeling. Volux® uses Vycross™ technology and has the highest concentration of HA of the Juvéderm product line (25 mg/mL), with results lasting about 18 months 34 . A phase 3, multisite, randomized, no‐treatment controlled study was completed in the United States in July 2021, with the goal of FDA approval in the United States in the near future 35…”

Five‐point liquid rhinoplasty: Results from a retrospective analysis of a novel standardized technique and considerations on safety

“…In our practice, Volux is now becoming the product of choice for injecting the nose. It has the highest HA concentration within the Vycross range (25 mg/ml), and comparative preclinical analyses suggest that it also has the highest cohesivity and G′ 3,22,24 . In a recent Italian study, Volux was found to be safe and effective for treatment of the nose, 15 and ultrasound analysis has shown that it integrates completely into the tissue within 30 days of implantation 25 .…”

“…To reduce product spreading, all procedures were performed using HA fillers with high G′ (and ideally also with high cohesivity). 22,23 In the nose, these specific rheological properties are more important than the particular product range used, and the "fivepoint liquid rhinoplasty" should be feasible using any appropriate HA filler with proven safety and efficacy. Nonetheless, 19 of the 20 patients in the present analysis received fillers from the Vycross range (Voluma or Volux).…”

“…It has the highest HA concentration within the Vycross range (25 mg/ml), and comparative preclinical analyses suggest that it also has the highest cohesivity and G′. 3,22,24 In a recent Italian study, Volux was found to be safe and effective for treatment of the nose, 15 and ultrasound F I G U R E 5 Aesthetic treatment of the nose using the five-point liquid rhinoplasty. A 35-year-old female before and immediately after treatment of the nose using 1.0 ml of Volux.…”